Table 3 9p24.1 Amplified renal cell carcinomas: 9p24.1 amplification status

Case 1 (Discovery cohort)

JAK2: 3.5-fold change

PD-L1: 3.5-fold change

PD-L2: 3.5-fold change

JAK2/INSL6: +

–

p-STAT3: 210

PD-L1: 240

PD-L2: 200

PD1: +++

Case 2 (Discovery cohort)

JAK2: 3.3-fold change

PD-L1: 3.1-fold change

PD-L2: not tested

JAK2/INSL6: +

–

p-STAT3: 170

PD-L1: 180

PD-L2: 0

PD1: +

Case 3 (Discovery cohort & Casuscelli et al.)

JAK2: 3.1-fold change

PD-L1: 3.1-fold change

PD-L2: not tested

JAK2/INSL6: +

–

p-STAT3: 0

PD-L1: 220

PD-L2: 40

PD1: +

Case 4 (Discovery cohort)

JAK2: 2.7-fold change

PD-L1: 2.7-fold change

PD-L2: 2.7-fold change

JAK2/INSL6: + PD-L1/PD-L2: +

–

p-STAT3: 10

PD-L1: 270

PD-L2: 10

PD1: +

Case 5 (Discovery cohort)

JAK2: 1.9-fold change

PD-L1: 1.9-fold change

PD-L2: not tested

JAK2/INSL6: +

–

p-STAT3: 100

PD-L1: 260

PD-L2: 10

PD1: 0

Case 6 (TCGA-BP-4983)

JAK2/PD-L1/PD-L2 amplified

JAK2/INSL6: + PD-L1/PD-L2: +

JAK2/PD-L1:

100^th percentile

PD-L2:

99^th percentile

p-STAT3: 30

PD-L1: 290

PD-L2: 0

PD1: +

Case 7 (Validation cohort)

–

JAK2/INSL6: + PD-L1/PD-L2: + 

–

–

PD-L1: 290

PD-L2: 0

–

Case 8 (Validation cohort)

–

JAK2/INSL6: + 

–

–

PD-L1: 245

PD-L2: 5

–

Case 9 (Validation cohort)

–

JAK2/INSL6: +

–

–

PD-L1: 140

PD-L2: 0

–

Case 10 (Validation cohort)

–

JAK2/INSL6: +

–

–

PD-L1: 85

PD-L2: 0

–

Case 11 (TCGA-CZ-5468)

JAK2/PD-L1/PD-L2 amplified

–

JAK2/PD-L1:

73^rd–78^th percentile

–

–

–

–

PD-L2: 94^th percentile

Case 12 (TCGA-B8-4143)

JAK2 amplified

–

JAK2:

72^nd percentile

–

–

–

–

Case 13

(Casuscelli et al.)

PD-L1 amplified

–

–

–

–

–

–